BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23964647)

  • 1. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
    Au WY; Lang BH; Fong BM; Mao KJ; Tam S
    Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
    [No Abstract]   [Full Text] [Related]  

  • 2. Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
    Firkin F
    Leuk Lymphoma; 2014 May; 55(5):977-8. PubMed ID: 24144311
    [No Abstract]   [Full Text] [Related]  

  • 3. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 4. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
    Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
    [No Abstract]   [Full Text] [Related]  

  • 6. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 7. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Galm O; Fabry U; Osieka R
    Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
    [No Abstract]   [Full Text] [Related]  

  • 9. Arsenic: a new place?
    Vincent PC
    Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
    [No Abstract]   [Full Text] [Related]  

  • 10. Arsenic compound approved as cancer chemotherapy agent.
    Miller JL
    Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 13. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
    Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
    Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
    [No Abstract]   [Full Text] [Related]  

  • 14. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 15. Ancient remedy performs new tricks.
    Mervis J
    Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
    Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
    Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
    [No Abstract]   [Full Text] [Related]  

  • 19. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 20. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
    Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
    Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.